<div id="readability-page-1"><h3>Valentine's Day Sale - 70% Off</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>The latest update is out from China NT Pharma Group Co., Ltd. ( (HK:1011) ). China NT Pharma Group Company Limited has requested a trading halt in its shares on the Hong Kong Stock Exchange, effective from the morning of 10 February 2026. The suspension comes as the company prepares to issue supplemental information related to its previously announced plan to issue convertible bonds under a general mandate. The halt indicates that key details on the convertible bond issuance are still pending, and trading will remain paused until the market receives further clarification. Investors and stakeholders are likely to watch closely for the additional disclosures, as the terms of the convertible bonds could affect the company’s capital structure and near-term financing strategy. The most recent analyst rating on (HK:1011) stock is a Hold with a HK$0.76 price target. To see the full list of analyst forecasts on China NT Pharma Group Co., Ltd. stock, see the HK:1011 Stock Forecast page. More about China NT Pharma Group Co., Ltd. China NT Pharma Group Company Limited is a pharmaceutical company listed on the Hong Kong Stock Exchange, focusing on the development and commercialization of healthcare and drug products for the Chinese and regional markets. The company operates under a board comprising executive, non-executive, and independent non-executive directors, reflecting a typical Hong Kong-listed corporate governance structure. Average Trading Volume: 299,298 Technical Sentiment Signal: Hold Current Market Cap: HK$532.7M Find detailed analytics on 1011 stock on TipRanks’ Stock Analysis page.</div>

159992

520690

01011

China NT Pharma Group Co., Ltd. has halted trading of its shares on the Hong Kong Stock Exchange as of February 10, 2026, pending details on its convertible bond issuance. The company is preparing to provide supplemental information regarding this plan, which could impact its capital structure and financing strategy. Analysts currently rate the stock as a Hold with a price target of HK$0.76. The company focuses on healthcare and drug product development for the Chinese market and has a market cap of HK$532.7M.

Tip Ranks

Yinhua CSI Innovative Drugs Industry ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

NT PHARMA

Guotai CSI Bio-medicine ETF

E Fund CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Minsheng Royal CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Bosera Hang Seng Health Care ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI 300 Health Care ETF

China Merchants CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

China Universal 800 Health Care ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC SSE STAR Biology and Medicine ETF

China NT Pharma Halts Trading Pending Details on Convertible Bond Issue